Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional) | PAR-19-287 | NCI | The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating… More | ||
| Research Centers for Cancer Systems Biology (U54 Clinical Trial Not Allowed) | RFA-CA-21-048 | NCI | The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC, https://csbconsortium.org/) supports the application of systems biology approaches to cancer research and includes U01… More | ||
| Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional) | PAR-19-389 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and… More | ||
| The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required) | PAR-21-111 | NCI | This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) | RFA-CA-21-010 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi… More | ||
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | PAR-20-314 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers… More | ||
| Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed) | PAR-19-199 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses.… More | ||
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional) | PA-19-112 | NCI | This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-… More | ||
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | PAR-21-330 | NCI | This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of… More | ||
| National Cancer Institute (NCI) Request for Information (RFI): Strategies for Matching Patients to Clinical Trials | NOT-CA-18-063 | NCI | N/A | National Cancer Institute NCI) Request Information RFI): Strategies Matching Patients Clinical Trials Notice Number: NOT-CA-18-063 Key Dates Release Date: April 11, 2018 Related Announcements None… More |